RECRUITING

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

Talk to us

Conditions

Breast CancerLocally Advanced Breast CancerSentinel Lymph Node Biopsy17-384

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to help the investigators determine how accurate the sentinel lymph node biopsy (SLNB) procedure is in identifying residual cancer cells after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer.

Official Title

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer: A Prospective Study

Quick Facts

Study Start:2017-08-17
Study Completion:2025-08-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03255577

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Female patients over 18 years of age with biopsy-proven breast cancer
  2. * Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
  3. * Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
  4. * Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
  1. * Patients with a prior history of ipsilateral breast cancer
  2. * Pregnant patients
  3. * Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
  4. * Patients not consenting to ALND

Contacts and Locations

Study Contact

Andrea Barrio, MD
CONTACT
646-888-5117
barrioa@mskcc.org
Monica Morrow, MD
CONTACT
646-888-5350

Principal Investigator

Andrea Barrio, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

BAPTIST ALLIANCE - MCI (Data Collection Only)
Miami, Florida, 33143
United States
Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up)
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen (Consent only and Follow Up)
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau (Consent only and Follow Up)
Uniondale, New York, 11553
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Andrea Barrio, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-08-17
Study Completion Date2025-08-30

Study Record Updates

Study Start Date2017-08-17
Study Completion Date2025-08-30

Terms related to this study

Keywords Provided by Researchers

  • Sentinel Lymph Node Biopsy
  • 17-384

Additional Relevant MeSH Terms

  • Breast Cancer
  • Locally Advanced Breast Cancer